8.43
+0.16(+1.93%)
Currency In USD
| Previous Close | 8.27 |
| Open | 8.37 |
| Day High | 8.62 |
| Day Low | 8.31 |
| 52-Week High | 14.93 |
| 52-Week Low | 3.9 |
| Volume | 587,774 |
| Average Volume | 1.4M |
| Market Cap | 820.99M |
| PE | -4.93 |
| EPS | -1.71 |
| Moving Average 50 Days | 11.53 |
| Moving Average 200 Days | 9.46 |
| Change | 0.16 |
If you invested $1000 in ORIC Pharmaceuticals, Inc. (ORIC) since IPO date, it would be worth $327.12 as of December 25, 2025 at a share price of $8.43. Whereas If you bought $1000 worth of ORIC Pharmaceuticals, Inc. (ORIC) shares 3 years ago, it would be worth $1,546.79 as of December 25, 2025 at a share price of $8.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
GlobeNewswire Inc.
Dec 06, 2025 1:00 AM GMT
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no si
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
GlobeNewswire Inc.
Dec 05, 2025 6:00 AM GMT
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
GlobeNewswire Inc.
Dec 05, 2025 2:45 AM GMT
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive safety profile